AbbVie Inc. Q4 2025 shows SKYRIZI/RINVOQ strength but diversification risks and M&A reliance. Click here to read this earnings analysis of ABBV stock.
Q4 2025 earnings call highlights: record sales, Skyrizi/Rinvoq momentum, 2026 guidance ($67B) and risks—read key takeaways.
The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and ...
AbbVie Inc. forecast 2026 profits above Wall Street’s expectations, though investors saw vulnerabilities in some of the ...
Kenvue Inc. (NYSE: KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February ...
Minute Maid helped make orange juice a year-round morning staple in 1946, when it started shipping cans of frozen juice ...
AbbVie's immunology portfolio was led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq, for which revenue rose 32.5% and 29.5% respectively. That offset a 26% decline for immune-disease ...
Turmeric and ibuprofen both reduce inflammation and pain, but they work in different ways. Learn how curcumin extract (from ...
Brain cells that promote tumor expansion for aggressive cancers such as glioblastoma can be “flipped” to instead inhibit that growth and potentially halt their spread, according to a study published ...
With a strong presence in Canada, Australia and New Zealand, Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results